with anaplastic lymphoma kinase (ALK) gene rearrangement mutations in about 4-7% of NSCLC tumours. 5 • Crizotinib (Xalkori®; Pfizer) was the first approved ALK tyrosine kinase inhibitor (TKI) and is a new therapy indicated for the treatment of patients with advanced or metastatic NSCLC, whose tumours are ALK-positive (ALK+). 6 • There is limited evidence available on the economic burden associated with advanced or metastatic NSCLC in Canada, and none evaluating the burden among crizotinib-treated ALK+ NSCLC patients.
OBJECTIVE
To characterize treatment patterns and to estimate the economic burden of illness among patients with locally advanced or metastatic ALK+ NSCLC who failed crizotinib therapy in Canada.
METHODS
This was a retrospective cohort study in patients diagnosed during a study period January 2010 to July 2014. A database was developed to capture information from the charts of all locally advanced or metastatic ALK+ NSCLC patients seen at six participating centers. One study center included patients up to May 2014 and another centre had a study end date of January 2015.
Inclusion criteria ALK+ NSCLC patients A registry data set was created with all reviewed charts of patients with locally advanced or metastatic ALK+ NSCLC; limited data were collected from all these charts. Detailed data was only collected for eligible patients including data on treatment and response to treatment, resource utilization, end of life care and status at end of study ( Figure 1 ). 
Costing Analysis
• Resource utilization characterization included the number and percent of patients with any utilization of each resource vs. no utilization. For individuals with non-zero utilization, the frequency of utilization was characterized by the total number of times they used the resource divided by total follow-up time in months, using a 2-stage approach.
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• Resource utilization estimates were extrapolated to cost estimates by multiplying the frequency of resource utilization to unit costs for specific resources. Total individual costs for hospitalizations, ER visits, physician visits, and laboratory and imaging tests were calculated. Mean cost per month and 95% CIs (confidence interval) are reported for costs based on the assumption of a normal distribution.
• To avoid underestimating the costs of treatment regimen, incomplete or censored patients were excluded (n=6).
• Sources of costs: unit costs were retrieved from IMSB databases (DeltaPA), unit costs of physician visits and imaging were retrieved from Ontario schedule of physician benefits, and unit costs for laboratory services were retrieved from Ontario schedule of laboratory services. Unit costs for adverse events were retrieved from Ontario Case Costing Initiative. For missing unit costs, data from literature was retrieved.
• All costs are reported in 2014 Canadian dollars.
RESULTS
Overall, 97 patients were screened for eligibility and included in the registry. 39 patients were receiving ongoing treatment with crizotinib and complete data were collected on 49 patients who failed crizotinib treatment and 9 crizotinibnaïve patients. Results presented focuses on 49 patients who failed treatment with crizotinib.
Baseline Demographics: The comorbidity index is based on the Charlson Comorbidity Index. It excludes cancer and metastases.
• All 49 patients received crizotinib as monotherapy. Median duration of treatment with crizotinib was 239 days (range, 100-464 days). Progression or adverse events were the main reasons for crizotinib discontinuation.
• Treatment patterns post crizotinib are presented in Table 2 . Overall, 35% and 33% of patients received concurrent palliative care and/or radiotherapy, respectively. However, it is understood that palliative care is underreported in this analysis.
• 20 patients did not receive further treatment and died with a median duration of 22 days. 
Economic Burden
Cost of active treatment
• The costs of systemic treatment were based on patients who completed the treatment regimen, in order to provide a more accurate estimation (i.e. censored patients were excluded from this calculation). 17 patients completed their treatment cycles and received 28 regimen options. The total mean regimen cost for systemic treatment post-crizotinib was $27,243 and excluding ceritinib therapy it was $16,473 ( Table 3 ). The mean regimen cost for ceritinib was the highest compared to all other agents used post-crizotinib, with a mean cost of $51,809. The total cost for systemic treatment postcrizotinib was $44,871 per patient, and $22,809 per patient excluding ceritinib ( Table 3 ) in 17 patients. 
Cost of Resource Utilization
• About 59% (n=29) of crizotinib failure patients had costs associated with resource utilization (Table 4 ).
• Hospitalizations were associated with the highest monthly cost incurred at $1,248 per month, per patient for all treatment lines and higher in the first and second-line treatments post-crizotinib discontinuation. The primary reason for hospitalizations was due to deterioration of NSCLC.
• Total costs associated with resource utilization during study period is reported in Table 5 . 
Survival
• Median progression free survival was 0.9, 6.5, and 20.4 months for patients receiving no treatment, non-ceritinib treatment and ceritinib treatment in first-line post-crizotinib, respectively. The median overall survival since discontinuing crizotinib was 0.9, 7.6 and 20.4 months in patients who had no further treatment, received non-ceritinib treatment and received ceritinib treatment, respectively.
DISCUSSION
• This study provides valuable information on the clinical characteristics, treatment patterns, and costs associated among patients with locally advanced or metastatic ALK+ NSCLC in Canada.
• A recently published study using chart review and claims data conducted among US ALK+ NSCLC patients, also reported substantial healthcare costs for this patient population; monthly healthcare costs USD $22,160, which was driven by pharmacy (USD $9,202), inpatient (USD $6,419), and outpatient radiotherapy (USD $2,888) and imaging (USD $1,179) costs.8
• Since the majority of patients discontinued treatment due to disease progression, there remains a strong need for effective second line treatment options post-crizotinib therapy.
LIMITATIONS
• Sample size included was small with the majority of patients receiving no further treatment.
• Cost associated with hospitalizations and ER visits reported herein are only due to adverse events reported. Hospitalizations or ER visits due to other reasons cannot be quantified in this analysis.
• Cost estimates for treatment regimens are estimates based on list prices and do not take into discounts provided to drug programs.
• Sample size was dependent on access to crizotinib, which received complete reimbursement in Canada as of October 2013.
• A bias in the inclusion of patients may have been introduced by two of the sites that had different study end dates than the other four sites.
• Additional treatment received after crizotinib failure may be closely related to the performance status and prognosis of the patient at that time
CONCLUSIONS
• Data from this study provide valuable information on patients with locally advanced or metastatic ALK+ NSCLC and allow for comparisons within crizotinib failure patients based on their postcrizotinib treatment.
• Treatment patterns post-crizotinib were heterogeneous highlighting the significant unmet need in patients failing crizotinib. In addition, patients receiving ceritinib had a longer survival, suggesting that ceritinib may provide survival benefit. • Estimated economic burden in patients who received active treatment post-crizotinib remains significant despite their poor prognosis.
